The Government has announced plans for a new UK Life Sciences Super Cluster, supported by £1 million of Government investment.
Bringing together industry, academia and the NHS, it will help deliver the next generation of medicines and technologies needed to support people suffering from chronic diseases.
At its heart will be the creation of Therapeutic Capability Clusters. These will be one-stop-shops for the UK?s top research in specific fields. They will bring together academic and NHS centres of excellence, which will work with industry to harness the UK?s expert capabilities and work on early stage clinical development and experimental medicine.
The new Life Sciences Super Cluster will be kick-started later this year with a pilot in immunology and inflammation focussing on disease areas such as asthma and rheumatoid arthritis.
The announcement caps off a year of action for UK Life Sciences. In July 2009, the OLS published the Life Sciences Blueprint setting out an ambitious and comprehensive set of measures to transform the UK operating environment. In the six months since publication, much has been achieved:
· A Patent Box, applying a 10% rate of corporation tax to patent-related income from April 2013. This will strengthen incentives for companies to invest in innovative activity and locate in the UK. Government will consult with business on the detailed design of the Box in time for Finance Bill 2011;
· A £21.5 million RegenMed programme managed by the Technology Strategy Board (TSB), which will support our growing and strategically-important regenerative medicine industry. The TSB launched two competitions, involving over 40 companies, in 2009 and will hold further competitions in 2010;
· An Innovation Pass, which will give patients earlier access to promising licensed medicines. A consultation on this three-year initiative began in November 2009. A one-year pilot will start in April 2010 with funding of £25 million;
Secretary of State for Business, Innovation and Skills Lord Mandelson said:
?Our Life Sciences industry is exactly the type of high-tech, high-value industry where Britain has real strengths and the potential for growth in the future.
?The Government has demonstrated that we are prepared to take real action to support Life Sciences and this is already having an impact on investment decisions, but this is just the beginning. We will maintain this momentum and continue to build a thriving environment for UK Life Science?
Health Secretary Andy Burnham said:
?Last month I set out a plan to reshape the NHS in the first half of this new decade ? to innovate at every level to meet the challenge of delivering preventative, people-centred care, that is also high-quality and highly productive. Working together with academia and industry, the NHS is championing new treatments, techniques and technologies to do this.
"As we move into a more challenging financial climate, successful research and innovation in preventing, diagnosing and treating disease will be key to increasing both the quality and productivity of services into the future. Joint initiatives with the Life Sciences Industry such as Therapeutic Capability Clusters, and the NHS Life Sciences Innovation Delivery Board are providing innovative ways to meet that challenge.?
Science and Innovation Minister Lord Drayson said:
?For life sciences to fulfill its vast economic promise, the NHS must be an engine for economic growth as well as providing the best healthcare free at the point of use. The OLS is helping to make that happen, but there is still a lot to do.?
News Release issued by the COI News Distribution Service on 26 January 2010
Added the 02 February 2010 in category Innovation News